strong organ growth modest ep
beat rais
ajg result per share forecast due modestli
better result brokerag segment off-set corpor shortfal risk
manag earn match expect although organ growth
forecast
commission/fe organ growth brokerag segment beat
forecast organ growth volatil howev base current trend
manag commentari regard market condit ajg initi
increas confid forecast look organ growth nearli
conserv assum organ growth sustain
assum compani continu activ acquir
maintain estim due healthi organ growth continu
model modest ebitdac margin improv brokerag segment
rais reiter buy
rais price object shift basi cash
earn line look comp addit
up assum multipl due obviou revenu
tailwind expect commerci price year oper leverag allow
on-going margin improv lead double-digit ep growth support
higher price-to-earnings multipl view compani ampl flexibl continu
enhanc oper acquisit pipelin continu robust
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
total benefit claim
arthur gallagh world fourth-largest
risk manag servic via network
subsidiari place p/c reinsur surplu
line manag employe benefit program
risk manag servic perform
manag loss control consult worker
believ one best-run middle-
market insur broker organ growth
respond better price econom
environ growth along good
expens disciplin allow continu
margin improv acquisit remain
attract avenu growth above-averag
dividend yield attract sustain
total invest
oper return averag asset
long term debt cap ratio ex fa
amtz dac pre-tax profit bef amtz dac
invest incom
gain book sale
chang acquisit earn out/oth
earn incom tax
provis incom tax
earn incom tax
provis incom tax
estimate
organ growth fee
earn incom tax
provis incom tax
invest incom
chang acquisit earn out/oth
earn incom tax
provis incom tax
invest incom
chang acquisit earn out/oth
earn incom tax
provis incom tax
tabl arthur gallagh risk manag corpor
earn incom tax
provis incom tax
organ growth fee
earn incom tax
provis incom tax
compani document bofa global research estim
invest incom
chang acquisit earn out/oth
earn incom tax
provis incom tax
po base cash ep estim premium
compar compani see justifi given better-than-expect
growth opportun driven success on-going strategi averag
organ growth oper leverag allow on-going margin improv
lead double-digit ep growth next sever year downsid risk
price object softer property-casualty price built
expect poor integr one sever acquisit lower industry-wid claim
frequenc hurt claim manag busi rise unemploy
could hurt claim manag busi expos worker compens
residu environment tax liabil relat synthet coal invest
chang health care regul impact benefit broke busi
chang dividend strategi compani
alison jacobowitz herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
